MedTrace Logo

Drug Coated Balloon vs. Drug-eluting Stent in Patients With Coronary Artery Disease

NCT07442500 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 470000

Last updated 2026-03-02

No results posted yet for this study

Summary

Studies exploring the feasibility of drug-eluting balloon (DCB) in de-novo coronary lesions are limited. There are scarce data comparing DCB with drug-eluting stent (DES) in patients with high bleeding risk (HBR), a situation in which long-term maintenance of dual antiplatelet therapy (DAPT) is a clinical dilemma. This target trial emulation aims to compare clinical outcomes between DCB angioplasty and conventional DES implantation in de-novo coronary lesions in patients with coronary artery disease.

Conditions

Interventions

DEVICE

Drug coated balloon

Patients receiving drug coated balloon angioplasty for de novo coronary artery disease

DEVICE

Drug-eluting stent

Patients receiving drug-eluting stent implantationfor de novo coronary artery disease

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Ki Hong Choi, MD, PhD · Samsung Medical Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07442500 on ClinicalTrials.gov